Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2022
Circulating level of serum secreted frizzled-related protein 5 decreases in polycystic ovary syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tasgoz Fatma Nurgul, Kender Erturk Nergis, Temur Muzaffer
Аннотация
OBJECTIVES: To analyse the SFRP-5 serum levels in PCOS and to investigate the relationship between SFRP-5 and other metabolic parameters in PCOS.
MATERIAL AND METHODS: This is a prospective case-control study carried out in a research hospital. A total of 88 subjects including 43 patients diagnosed PCOS according to Rotterdam criteria and age -BMI matched 45 healthy controls were evaluated. Serum SFRP5, fasting blood glucose, insulin levels and HOMA-IR scores of the groups were determined and compared. The cut-off of SFRP-5 for detecting PCOS was calculated.
RESULTS: Serum SFRP-5 levels were lower in PCOS group compared to the controls (290.13 ± 187.66 ng/mL vs 533.03 ± 208.55 ng/mL, p < 0.001). There was no correlation in the PCOS group regarding SFRP-5 and other parameters. The role of SFRP-5 to predict the PCOS risk was assessed with receiver operating curve (ROC). The sensitivity of SFRP-5 was 74.4% and the specificity was 75.6% at a threshold ≤388.38 ng/ml in PCOS.
CONCLUSION: SFRP-5 could be a beneficial marker for PCOS diagnosis, follow-up and treatment.
MATERIAL AND METHODS: This is a prospective case-control study carried out in a research hospital. A total of 88 subjects including 43 patients diagnosed PCOS according to Rotterdam criteria and age -BMI matched 45 healthy controls were evaluated. Serum SFRP5, fasting blood glucose, insulin levels and HOMA-IR scores of the groups were determined and compared. The cut-off of SFRP-5 for detecting PCOS was calculated.
RESULTS: Serum SFRP-5 levels were lower in PCOS group compared to the controls (290.13 ± 187.66 ng/mL vs 533.03 ± 208.55 ng/mL, p < 0.001). There was no correlation in the PCOS group regarding SFRP-5 and other parameters. The role of SFRP-5 to predict the PCOS risk was assessed with receiver operating curve (ROC). The sensitivity of SFRP-5 was 74.4% and the specificity was 75.6% at a threshold ≤388.38 ng/ml in PCOS.
CONCLUSION: SFRP-5 could be a beneficial marker for PCOS diagnosis, follow-up and treatment.